CATHERINE ESTIPONA: Open Payments
NPI 1760556534 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$690 in 29 payments from 9 companies in 2025. Trend: 2023 $711 · 2024 $518 · 2025 $690
Food & beverage: $690
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $188 |
| Amgen Inc. | 5 | $121 |
| Astellas Pharma US Inc | 3 | $101 |
| Novo Nordisk Inc | 4 | $94 |
| PFIZER INC. | 3 | $76 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Lilly USA, LLC | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: VRAYLAR, Veozah, NURTEC ODT, Ozempic, KRYSTEXXA, OTEZLA, GEMTESA, MOUNJARO.
Industry payments across NV — which companies pay providers there.
